Abiopharma

🔍 Whalen Amanda (Executive)

Company: Klaviyo, Inc. (KVYO)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 265,151 shares of Series A Common Stock (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 677,576.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 227,272 shares of Series A Common Stock (Direct)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 904,848.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 4,293 shares of Series A Common Stock (Direct)
  Date: 2026-04-16 | Code: C | equity_swap_involved: 0 | shares_owned_after: 909,141.00 | transaction_form_type: 4 | Footnotes: F4, F5
• Sold 14,000 shares of Series A Common Stock at $18.54 per share (Direct)
  Date: 2026-04-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 895,141.00 | transaction_form_type: 4 | Footnotes: F4, F6, F7
• Sold 4,293 shares of Series B Common Stock (Derivative)
  Date: 2026-04-16 | Code: C | equity_swap_involved: 0 | shares_owned_after: 297,112.00 | transaction_form_type: 4 | Footnotes: F5, F4, F5, F5, F8

Footnotes:

• F1: Represents restricted stock units ("RSUs") awarded under the Issuer's 2023 Stock Option and Incentive Plan (the "Plan"), each representing the contingent right to receive one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), upon vesting and settlement. The RSUs vest as follows: (i) 50% of the RSUs will vest in eight equal quarterly installments, with the first such installment vesting on May 15, 2026, and (ii) thereafter the remaining 50% of the RSUs will vest in four equal quarterly installments, subject to the Reporting Person's continued service on each such vesting date.
• F2: Represents performance stock units ("PSUs") awarded under the Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement. The PSUs will vest in up to three tranches over a two-year measurement period, subject to the achievement of specified performance targets tied to the trading price of the Series A Common Stock and the Reporting Person's continued service in the same or substantially equivalent position as the Reporting Person held as of the grant date through the applicable vesting date. Each tranche of PSUs will vest only if the average closing price of the Series A Common Stock for a period of at least sixty consecutive calendar days is at or above a specified dollar value during the applicable measurement period.
• F3: (continued) The stock price targets for tranches 1 through 3 are $30.00, $50.00, and $75.00 per share, respectively, subject to proportionate adjustment in the event of any stock split or other similar change in the Issuer's capital stock.
• F4: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2025.
• F5: Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of Series A Common Stock, and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date.
• F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.34 to $18.98 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: Consists of (i) 42,687 shares of Series A Common Stock; (ii) 625,182 unvested RSUs awarded under the Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement; and (iii) 227,272 unvested PSUs awarded under the Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement.
• F8: Consists of (i) 262,737 shares of Series B Common Stock and (ii) 34,375 unvested RSUs awarded under the Issuer's 2015 Stock Incentive Plan, each representing the contingent right to receive one share of Series B Common Stock upon vesting and settlement.